 Nicholas Cost
Concepts (397)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 66 | 2025 | 408 | 16.600 |
Why?
| | Wilms Tumor | 36 | 2025 | 88 | 10.890 |
Why?
| | Testicular Neoplasms | 23 | 2023 | 115 | 8.890 |
Why?
| | Nephrectomy | 35 | 2025 | 157 | 6.420 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 14 | 2023 | 79 | 5.850 |
Why?
| | Lymph Node Excision | 13 | 2024 | 169 | 4.010 |
Why?
| | Carcinoma, Renal Cell | 18 | 2025 | 225 | 3.910 |
Why?
| | Rhabdoid Tumor | 6 | 2025 | 101 | 2.870 |
Why?
| | Lymph Nodes | 9 | 2023 | 502 | 2.550 |
Why?
| | Neoplasm Staging | 26 | 2025 | 1401 | 2.420 |
Why?
| | Urology | 8 | 2024 | 61 | 2.340 |
Why?
| | Child | 100 | 2025 | 22414 | 2.200 |
Why?
| | Urinary Bladder | 5 | 2024 | 195 | 2.140 |
Why?
| | Medical Oncology | 7 | 2023 | 317 | 2.100 |
Why?
| | Lower Urinary Tract Symptoms | 3 | 2025 | 61 | 2.080 |
Why?
| | Child, Preschool | 69 | 2025 | 11512 | 2.000 |
Why?
| | Orchiectomy | 8 | 2023 | 75 | 1.960 |
Why?
| | Urodynamics | 4 | 2025 | 49 | 1.950 |
Why?
| | Laparoscopy | 12 | 2024 | 463 | 1.930 |
Why?
| | Rhabdomyosarcoma | 5 | 2022 | 74 | 1.800 |
Why?
| | Hydronephrosis | 6 | 2019 | 36 | 1.800 |
Why?
| | Adolescent | 72 | 2025 | 22130 | 1.760 |
Why?
| | Urinary Tract | 3 | 2025 | 50 | 1.760 |
Why?
| | Infant | 59 | 2025 | 9843 | 1.750 |
Why?
| | Vincristine | 3 | 2024 | 132 | 1.690 |
Why?
| | Lymphatic Metastasis | 12 | 2022 | 326 | 1.600 |
Why?
| | Urologic Surgical Procedures | 8 | 2019 | 118 | 1.570 |
Why?
| | Urologists | 3 | 2017 | 17 | 1.560 |
Why?
| | Urologic Neoplasms | 4 | 2017 | 30 | 1.490 |
Why?
| | Radiotherapy | 2 | 2025 | 208 | 1.450 |
Why?
| | Male | 107 | 2025 | 70179 | 1.420 |
Why?
| | Humans | 157 | 2025 | 141754 | 1.410 |
Why?
| | Kidney Pelvis | 6 | 2015 | 24 | 1.390 |
Why?
| | Robotics | 6 | 2015 | 88 | 1.380 |
Why?
| | Pelvic Neoplasms | 3 | 2025 | 25 | 1.370 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2022 | 90 | 1.360 |
Why?
| | Prognosis | 24 | 2025 | 4080 | 1.290 |
Why?
| | Pediatrics | 7 | 2025 | 1100 | 1.290 |
Why?
| | Practice Patterns, Physicians' | 6 | 2024 | 1344 | 1.270 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2021 | 256 | 1.210 |
Why?
| | Organ Sparing Treatments | 4 | 2023 | 36 | 1.180 |
Why?
| | Doxorubicin | 2 | 2021 | 360 | 1.120 |
Why?
| | Ureteral Obstruction | 5 | 2015 | 64 | 1.090 |
Why?
| | Urinary Bladder Diseases | 2 | 2019 | 18 | 1.080 |
Why?
| | Kidney | 9 | 2023 | 1482 | 1.060 |
Why?
| | Retrospective Studies | 48 | 2025 | 16374 | 1.030 |
Why?
| | Female | 84 | 2025 | 75943 | 1.010 |
Why?
| | Tumor Burden | 6 | 2019 | 312 | 0.970 |
Why?
| | Young Adult | 34 | 2025 | 13749 | 0.920 |
Why?
| | Kidney Diseases, Cystic | 3 | 2021 | 25 | 0.910 |
Why?
| | Rhabdomyosarcoma, Embryonal | 2 | 2022 | 21 | 0.900 |
Why?
| | Nephrons | 9 | 2023 | 22 | 0.880 |
Why?
| | Biopsy | 6 | 2024 | 1083 | 0.860 |
Why?
| | Ribonuclease III | 3 | 2021 | 44 | 0.850 |
Why?
| | Sarcoma, Clear Cell | 3 | 2025 | 9 | 0.840 |
Why?
| | Mixed Tumor, Malignant | 1 | 2023 | 5 | 0.840 |
Why?
| | DEAD-box RNA Helicases | 3 | 2021 | 86 | 0.820 |
Why?
| | Sertoli-Leydig Cell Tumor | 3 | 2021 | 8 | 0.820 |
Why?
| | Surgeons | 4 | 2025 | 336 | 0.800 |
Why?
| | Hypospadias | 4 | 2011 | 31 | 0.800 |
Why?
| | Seminoma | 3 | 2021 | 20 | 0.780 |
Why?
| | Sarcoma | 3 | 2024 | 190 | 0.760 |
Why?
| | Urologic Surgical Procedures, Male | 4 | 2018 | 32 | 0.760 |
Why?
| | Spermatic Cord Torsion | 2 | 2013 | 5 | 0.750 |
Why?
| | Leydig Cell Tumor | 3 | 2021 | 8 | 0.750 |
Why?
| | Age Factors | 13 | 2025 | 3294 | 0.730 |
Why?
| | Disease-Free Survival | 7 | 2022 | 718 | 0.730 |
Why?
| | Surgical Oncology | 2 | 2025 | 28 | 0.730 |
Why?
| | Paraganglioma | 1 | 2022 | 53 | 0.720 |
Why?
| | Cryptorchidism | 2 | 2019 | 16 | 0.720 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.690 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 132 | 0.680 |
Why?
| | Pheochromocytoma | 2 | 2019 | 58 | 0.670 |
Why?
| | Neoplasms | 7 | 2025 | 2747 | 0.670 |
Why?
| | Tomography, X-Ray Computed | 9 | 2021 | 2765 | 0.660 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2024 | 1078 | 0.650 |
Why?
| | Molecular Targeted Therapy | 3 | 2025 | 420 | 0.650 |
Why?
| | Follow-Up Studies | 18 | 2025 | 5212 | 0.640 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 3 | 0.640 |
Why?
| | Infant, Newborn | 11 | 2023 | 6289 | 0.630 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 2 | 2017 | 5 | 0.620 |
Why?
| | Cystectomy | 1 | 2019 | 42 | 0.610 |
Why?
| | Smooth Muscle Myosins | 1 | 2019 | 6 | 0.610 |
Why?
| | Myosin Light Chains | 1 | 2019 | 28 | 0.610 |
Why?
| | Muscle Relaxation | 1 | 2019 | 29 | 0.610 |
Why?
| | Neoplasm Invasiveness | 7 | 2017 | 510 | 0.610 |
Why?
| | Retroperitoneal Space | 2 | 2024 | 17 | 0.590 |
Why?
| | Treatment Outcome | 27 | 2025 | 11181 | 0.590 |
Why?
| | Diagnostic Imaging | 3 | 2022 | 327 | 0.590 |
Why?
| | Fertility Preservation | 3 | 2024 | 54 | 0.580 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 57 | 0.570 |
Why?
| | Catheterization | 1 | 2019 | 182 | 0.570 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 5974 | 0.570 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 131 | 0.560 |
Why?
| | von Hippel-Lindau Disease | 1 | 2018 | 12 | 0.560 |
Why?
| | Testicular Diseases | 1 | 2018 | 7 | 0.560 |
Why?
| | Neoadjuvant Therapy | 4 | 2021 | 424 | 0.560 |
Why?
| | Health Care Surveys | 2 | 2017 | 566 | 0.560 |
Why?
| | Specimen Handling | 1 | 2019 | 182 | 0.560 |
Why?
| | Calculi | 1 | 2018 | 16 | 0.550 |
Why?
| | Survival Rate | 11 | 2025 | 1972 | 0.540 |
Why?
| | Risk Assessment | 11 | 2025 | 3508 | 0.540 |
Why?
| | Orchiopexy | 3 | 2019 | 6 | 0.540 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2012 | 529 | 0.540 |
Why?
| | Conservative Treatment | 1 | 2018 | 35 | 0.530 |
Why?
| | Kaplan-Meier Estimate | 6 | 2019 | 910 | 0.530 |
Why?
| | Radiation Exposure | 1 | 2017 | 55 | 0.520 |
Why?
| | Kidney Medulla | 1 | 2016 | 31 | 0.520 |
Why?
| | Cytodiagnosis | 1 | 2017 | 32 | 0.520 |
Why?
| | Frozen Sections | 1 | 2017 | 25 | 0.510 |
Why?
| | Critical Pathways | 1 | 2018 | 106 | 0.510 |
Why?
| | Angiomyolipoma | 1 | 2016 | 23 | 0.510 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2567 | 0.500 |
Why?
| | Cancer Survivors | 1 | 2021 | 302 | 0.490 |
Why?
| | Teratoma | 2 | 2017 | 121 | 0.490 |
Why?
| | Postoperative Care | 1 | 2018 | 280 | 0.490 |
Why?
| | Muscle Contraction | 1 | 2019 | 435 | 0.490 |
Why?
| | Tuberous Sclerosis | 1 | 2016 | 55 | 0.480 |
Why?
| | Granuloma, Plasma Cell | 1 | 2015 | 13 | 0.480 |
Why?
| | Robotic Surgical Procedures | 2 | 2015 | 149 | 0.470 |
Why?
| | Survival Analysis | 5 | 2019 | 1320 | 0.460 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1793 | 0.460 |
Why?
| | Adult | 25 | 2025 | 39391 | 0.450 |
Why?
| | Pediatricians | 1 | 2016 | 131 | 0.450 |
Why?
| | Glomerular Filtration Rate | 4 | 2018 | 752 | 0.450 |
Why?
| | Abdominal Neoplasms | 2 | 2025 | 47 | 0.450 |
Why?
| | Neurofibromatosis 1 | 2 | 2019 | 56 | 0.440 |
Why?
| | Prospective Studies | 11 | 2025 | 7777 | 0.440 |
Why?
| | Adenoma | 1 | 2016 | 221 | 0.430 |
Why?
| | Societies, Medical | 5 | 2025 | 859 | 0.430 |
Why?
| | Cause of Death | 1 | 2016 | 441 | 0.420 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2012 | 2135 | 0.420 |
Why?
| | Prostatic Neoplasms | 2 | 2019 | 1049 | 0.420 |
Why?
| | Hypertension | 1 | 2022 | 1254 | 0.410 |
Why?
| | Germ-Line Mutation | 3 | 2025 | 168 | 0.400 |
Why?
| | Minimally Invasive Surgical Procedures | 4 | 2025 | 181 | 0.400 |
Why?
| | Acute-Phase Proteins | 1 | 2013 | 66 | 0.400 |
Why?
| | Lipocalins | 1 | 2013 | 36 | 0.400 |
Why?
| | Ultrasonography | 5 | 2019 | 761 | 0.400 |
Why?
| | Databases, Factual | 5 | 2019 | 1448 | 0.390 |
Why?
| | Infertility | 2 | 2024 | 55 | 0.390 |
Why?
| | Radiation Protection | 1 | 2013 | 39 | 0.390 |
Why?
| | Ovarian Neoplasms | 3 | 2021 | 581 | 0.390 |
Why?
| | SEER Program | 5 | 2019 | 221 | 0.390 |
Why?
| | Patient Education as Topic | 1 | 2018 | 779 | 0.380 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2013 | 103 | 0.380 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2016 | 475 | 0.380 |
Why?
| | Combined Modality Therapy | 5 | 2025 | 1249 | 0.380 |
Why?
| | Biopsy, Needle | 1 | 2013 | 187 | 0.370 |
Why?
| | Multimodal Imaging | 1 | 2013 | 120 | 0.370 |
Why?
| | Glucose Transporter Type 1 | 1 | 2012 | 48 | 0.370 |
Why?
| | Carcinoma, Medullary | 2 | 2025 | 17 | 0.360 |
Why?
| | United States | 14 | 2025 | 15310 | 0.360 |
Why?
| | Multivariate Analysis | 5 | 2018 | 1498 | 0.350 |
Why?
| | Primary Prevention | 1 | 2013 | 202 | 0.350 |
Why?
| | Incidence | 7 | 2019 | 2806 | 0.350 |
Why?
| | Neoplasm Metastasis | 5 | 2019 | 676 | 0.350 |
Why?
| | Positron-Emission Tomography | 1 | 2013 | 310 | 0.350 |
Why?
| | Codon | 1 | 2011 | 92 | 0.350 |
Why?
| | Proline | 1 | 2011 | 80 | 0.340 |
Why?
| | Vena Cava, Inferior | 1 | 2011 | 74 | 0.330 |
Why?
| | Seasons | 1 | 2013 | 546 | 0.330 |
Why?
| | Suburethral Slings | 1 | 2010 | 8 | 0.330 |
Why?
| | Temperature | 1 | 2013 | 669 | 0.320 |
Why?
| | Arginine | 1 | 2011 | 260 | 0.320 |
Why?
| | Hernia, Ventral | 1 | 2010 | 24 | 0.320 |
Why?
| | Sex Factors | 3 | 2024 | 2063 | 0.320 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 624 | 0.310 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2010 | 39 | 0.310 |
Why?
| | Urinary Incontinence | 1 | 2010 | 66 | 0.310 |
Why?
| | Mouth Mucosa | 1 | 2009 | 90 | 0.300 |
Why?
| | Ureter | 4 | 2014 | 34 | 0.300 |
Why?
| | Campomelic Dysplasia | 1 | 2009 | 2 | 0.300 |
Why?
| | Dysgerminoma | 1 | 2009 | 7 | 0.300 |
Why?
| | Angiogenesis Inhibitors | 1 | 2011 | 230 | 0.300 |
Why?
| | Length of Stay | 4 | 2025 | 1263 | 0.300 |
Why?
| | Skin Transplantation | 1 | 2009 | 85 | 0.300 |
Why?
| | Urethra | 2 | 2011 | 56 | 0.300 |
Why?
| | Urolithiasis | 1 | 2009 | 10 | 0.300 |
Why?
| | Recovery of Function | 1 | 2013 | 684 | 0.300 |
Why?
| | Clitoris | 1 | 2009 | 9 | 0.300 |
Why?
| | SOX9 Transcription Factor | 1 | 2009 | 26 | 0.300 |
Why?
| | Brachytherapy | 2 | 2021 | 131 | 0.290 |
Why?
| | Venous Thrombosis | 1 | 2011 | 192 | 0.290 |
Why?
| | Bone Neoplasms | 1 | 2011 | 253 | 0.290 |
Why?
| | Attitude of Health Personnel | 1 | 2016 | 1183 | 0.280 |
Why?
| | Surgical Flaps | 1 | 2009 | 144 | 0.280 |
Why?
| | Time Factors | 8 | 2019 | 6966 | 0.280 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 820 | 0.270 |
Why?
| | Aged | 12 | 2025 | 24746 | 0.270 |
Why?
| | Neuroblastoma | 2 | 2025 | 163 | 0.260 |
Why?
| | Middle Aged | 14 | 2025 | 34647 | 0.260 |
Why?
| | Calcinosis | 1 | 2009 | 238 | 0.260 |
Why?
| | Health Promotion | 1 | 2013 | 759 | 0.250 |
Why?
| | Risk Factors | 8 | 2018 | 10482 | 0.250 |
Why?
| | Postoperative Complications | 6 | 2025 | 2821 | 0.240 |
Why?
| | Ureterocele | 2 | 2016 | 7 | 0.240 |
Why?
| | Vesico-Ureteral Reflux | 2 | 2016 | 35 | 0.230 |
Why?
| | Biomarkers, Tumor | 3 | 2025 | 1258 | 0.230 |
Why?
| | Mitotic Index | 2 | 2015 | 24 | 0.230 |
Why?
| | Carcinoma, Papillary | 1 | 2025 | 81 | 0.220 |
Why?
| | Kidney Diseases | 1 | 2009 | 409 | 0.220 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 919 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 5 | 2025 | 2375 | 0.220 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2169 | 0.220 |
Why?
| | Hypertrophy | 2 | 2019 | 136 | 0.220 |
Why?
| | Perioperative Care | 2 | 2024 | 227 | 0.220 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2013 | 381 | 0.210 |
Why?
| | Clinical Competence | 2 | 2025 | 1205 | 0.210 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2024 | 63 | 0.200 |
Why?
| | Gonadal Dysgenesis | 1 | 2023 | 7 | 0.200 |
Why?
| | Adrenocortical Carcinoma | 1 | 2024 | 66 | 0.200 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2024 | 192 | 0.200 |
Why?
| | Mast Cells | 1 | 2024 | 153 | 0.190 |
Why?
| | Tumor Suppressor Proteins | 1 | 2025 | 326 | 0.190 |
Why?
| | Lymphocytes | 1 | 2025 | 398 | 0.190 |
Why?
| | Pubic Bone | 1 | 2022 | 6 | 0.190 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2025 | 439 | 0.180 |
Why?
| | Monocytes | 1 | 2025 | 579 | 0.180 |
Why?
| | Urination | 1 | 2022 | 48 | 0.180 |
Why?
| | Algorithms | 1 | 2009 | 1768 | 0.180 |
Why?
| | Sertoli Cell Tumor | 1 | 2021 | 2 | 0.180 |
Why?
| | Blood Platelets | 1 | 2025 | 437 | 0.170 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2022 | 115 | 0.170 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2021 | 21 | 0.170 |
Why?
| | Testosterone | 2 | 2015 | 405 | 0.170 |
Why?
| | Aniridia | 1 | 2020 | 5 | 0.170 |
Why?
| | PAX6 Transcription Factor | 1 | 2020 | 21 | 0.170 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1502 | 0.170 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2021 | 43 | 0.170 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2019 | 110 | 0.170 |
Why?
| | Reoperation | 3 | 2014 | 592 | 0.170 |
Why?
| | Codon, Nonsense | 1 | 2020 | 43 | 0.170 |
Why?
| | Pneumothorax | 1 | 2021 | 50 | 0.170 |
Why?
| | Interleukin-2 | 1 | 2022 | 456 | 0.160 |
Why?
| | Eye Proteins | 1 | 2020 | 93 | 0.160 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1057 | 0.160 |
Why?
| | Penile Neoplasms | 1 | 2019 | 6 | 0.160 |
Why?
| | Syndrome | 1 | 2021 | 378 | 0.160 |
Why?
| | Priapism | 1 | 2019 | 11 | 0.160 |
Why?
| | Patient Selection | 3 | 2013 | 688 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2024 | 2064 | 0.160 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2019 | 44 | 0.160 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2019 | 8 | 0.150 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2019 | 20 | 0.150 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2019 | 10 | 0.150 |
Why?
| | Proportional Hazards Models | 3 | 2011 | 1268 | 0.150 |
Why?
| | Computers | 1 | 2019 | 68 | 0.150 |
Why?
| | Decision Trees | 1 | 2019 | 82 | 0.150 |
Why?
| | Puberty, Precocious | 1 | 2019 | 13 | 0.150 |
Why?
| | Genotype | 2 | 2016 | 1866 | 0.150 |
Why?
| | Neutrophils | 1 | 2025 | 1282 | 0.150 |
Why?
| | Dermatofibrosarcoma | 1 | 2018 | 7 | 0.150 |
Why?
| | Hospitals | 1 | 2023 | 696 | 0.150 |
Why?
| | Genetic Testing | 2 | 2019 | 463 | 0.140 |
Why?
| | Diagnostic Errors | 1 | 2019 | 178 | 0.140 |
Why?
| | Self-Examination | 1 | 2018 | 2 | 0.140 |
Why?
| | Proton Therapy | 1 | 2018 | 14 | 0.140 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 234 | 0.140 |
Why?
| | Animals | 6 | 2025 | 37749 | 0.140 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 178 | 0.140 |
Why?
| | Registries | 3 | 2025 | 2144 | 0.140 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 219 | 0.140 |
Why?
| | Mutation | 1 | 2009 | 4015 | 0.130 |
Why?
| | Aged, 80 and over | 4 | 2019 | 7923 | 0.130 |
Why?
| | Preoperative Period | 1 | 2018 | 144 | 0.130 |
Why?
| | Asymptomatic Diseases | 1 | 2018 | 92 | 0.130 |
Why?
| | Drug Utilization | 1 | 2018 | 169 | 0.130 |
Why?
| | Analysis of Variance | 2 | 2017 | 1321 | 0.130 |
Why?
| | Unnecessary Procedures | 1 | 2017 | 53 | 0.130 |
Why?
| | Ultrasonography, Doppler | 1 | 2018 | 122 | 0.130 |
Why?
| | Testis | 1 | 2018 | 158 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2025 | 890 | 0.130 |
Why?
| | Intraoperative Period | 1 | 2017 | 68 | 0.130 |
Why?
| | General Surgery | 1 | 2019 | 199 | 0.130 |
Why?
| | Europe | 1 | 2018 | 411 | 0.130 |
Why?
| | Mice | 3 | 2024 | 18109 | 0.120 |
Why?
| | Logistic Models | 3 | 2018 | 2092 | 0.120 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 1406 | 0.120 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1275 | 0.120 |
Why?
| | Feasibility Studies | 2 | 2018 | 1027 | 0.120 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 323 | 0.120 |
Why?
| | North America | 1 | 2016 | 307 | 0.120 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 457 | 0.120 |
Why?
| | Certification | 1 | 2016 | 119 | 0.120 |
Why?
| | Translocation, Genetic | 2 | 2018 | 109 | 0.120 |
Why?
| | Models, Statistical | 1 | 2019 | 671 | 0.110 |
Why?
| | Learning | 1 | 2019 | 439 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1570 | 0.110 |
Why?
| | History, 21st Century | 1 | 2015 | 220 | 0.110 |
Why?
| | Phosphorylation | 1 | 2019 | 1774 | 0.110 |
Why?
| | Anaplasia | 2 | 2024 | 7 | 0.110 |
Why?
| | Matched-Pair Analysis | 1 | 2014 | 38 | 0.110 |
Why?
| | Forecasting | 1 | 2016 | 384 | 0.110 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2014 | 17 | 0.110 |
Why?
| | Genitalia, Female | 1 | 2014 | 41 | 0.110 |
Why?
| | Ureteral Calculi | 1 | 2014 | 12 | 0.110 |
Why?
| | TRPM Cation Channels | 1 | 2014 | 75 | 0.110 |
Why?
| | Kidney Function Tests | 1 | 2014 | 159 | 0.100 |
Why?
| | Inflammation | 1 | 2025 | 2902 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 434 | 0.100 |
Why?
| | Disease Management | 1 | 2017 | 633 | 0.100 |
Why?
| | Lipocalin-2 | 1 | 2013 | 79 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3737 | 0.100 |
Why?
| | Estrogens | 1 | 2015 | 368 | 0.100 |
Why?
| | Blood Vessels | 1 | 2014 | 180 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2020 | 962 | 0.090 |
Why?
| | Tissue Array Analysis | 1 | 2012 | 52 | 0.090 |
Why?
| | Spermatic Cord | 1 | 2012 | 1 | 0.090 |
Why?
| | Creatinine | 1 | 2014 | 490 | 0.090 |
Why?
| | Autophagy | 1 | 2014 | 287 | 0.090 |
Why?
| | Cohort Studies | 5 | 2016 | 5815 | 0.090 |
Why?
| | Monitoring, Physiologic | 1 | 2014 | 285 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 209 | 0.090 |
Why?
| | Radiation Dosage | 1 | 2013 | 191 | 0.090 |
Why?
| | Fetal Diseases | 1 | 2013 | 181 | 0.090 |
Why?
| | Surgical Wound Dehiscence | 1 | 2011 | 22 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2018 | 857 | 0.090 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2011 | 71 | 0.080 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 5697 | 0.080 |
Why?
| | Thrombectomy | 1 | 2011 | 75 | 0.080 |
Why?
| | Bevacizumab | 1 | 2011 | 139 | 0.080 |
Why?
| | Compliance | 1 | 2010 | 50 | 0.080 |
Why?
| | Texas | 1 | 2011 | 262 | 0.080 |
Why?
| | Referral and Consultation | 1 | 2016 | 799 | 0.080 |
Why?
| | Pyrroles | 1 | 2011 | 210 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 521 | 0.080 |
Why?
| | Sulfonamides | 1 | 2014 | 567 | 0.080 |
Why?
| | Rectum | 1 | 2011 | 192 | 0.080 |
Why?
| | Penis | 2 | 2019 | 34 | 0.080 |
Why?
| | Muscle, Smooth | 1 | 2010 | 154 | 0.080 |
Why?
| | Operative Time | 3 | 2014 | 154 | 0.080 |
Why?
| | Internship and Residency | 1 | 2019 | 1240 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 771 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1056 | 0.070 |
Why?
| | Radiography | 1 | 2011 | 844 | 0.070 |
Why?
| | Alleles | 1 | 2011 | 891 | 0.070 |
Why?
| | Pilot Projects | 1 | 2014 | 1826 | 0.070 |
Why?
| | Remission, Spontaneous | 2 | 2021 | 40 | 0.070 |
Why?
| | MicroRNAs | 1 | 2014 | 692 | 0.070 |
Why?
| | Congenital Abnormalities | 1 | 2008 | 105 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2075 | 0.070 |
Why?
| | Indoles | 1 | 2011 | 478 | 0.070 |
Why?
| | Biomarkers | 2 | 2019 | 4190 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2014 | 3597 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2012 | 599 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2903 | 0.060 |
Why?
| | Pregnancy | 1 | 2018 | 7092 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 5169 | 0.060 |
Why?
| | Cystoscopy | 2 | 2016 | 21 | 0.060 |
Why?
| | Nephroma, Mesoblastic | 1 | 2025 | 3 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 913 | 0.060 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2024 | 14 | 0.060 |
Why?
| | Image-Guided Biopsy | 1 | 2024 | 39 | 0.050 |
Why?
| | Adrenalectomy | 1 | 2024 | 70 | 0.050 |
Why?
| | Nephroureterectomy | 1 | 2023 | 2 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1474 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 313 | 0.050 |
Why?
| | Sexual Development | 1 | 2023 | 17 | 0.050 |
Why?
| | Gonads | 1 | 2023 | 23 | 0.050 |
Why?
| | Lymphoma | 1 | 2024 | 228 | 0.050 |
Why?
| | Pancreatectomy | 1 | 2025 | 262 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 547 | 0.050 |
Why?
| | Analgesics, Opioid | 2 | 2024 | 1123 | 0.040 |
Why?
| | Germany | 1 | 2020 | 132 | 0.040 |
Why?
| | Accreditation | 1 | 2019 | 93 | 0.040 |
Why?
| | Hyperplasia | 1 | 2019 | 176 | 0.040 |
Why?
| | Mohs Surgery | 1 | 2018 | 28 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 23 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2024 | 741 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2018 | 311 | 0.030 |
Why?
| | Mosaicism | 1 | 2017 | 74 | 0.030 |
Why?
| | Ureteroscopy | 1 | 2016 | 13 | 0.030 |
Why?
| | Monitoring, Intraoperative | 1 | 2016 | 65 | 0.030 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 15 | 0.030 |
Why?
| | Caveolin 1 | 1 | 2014 | 22 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 526 | 0.030 |
Why?
| | Ureterostomy | 1 | 2014 | 2 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 250 | 0.030 |
Why?
| | Oncogenes | 1 | 2014 | 118 | 0.030 |
Why?
| | Bone Marrow Neoplasms | 1 | 2013 | 4 | 0.030 |
Why?
| | Cicatrix | 1 | 2014 | 67 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 481 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 691 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 469 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2014 | 737 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2011 | 29 | 0.020 |
Why?
| | Area Under Curve | 1 | 2011 | 324 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2011 | 316 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1977 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 197 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 3014 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 372 | 0.020 |
Why?
| | Dihydrolipoamide Dehydrogenase | 1 | 2009 | 6 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1435 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3495 | 0.020 |
Why?
|
|
Cost's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|